Adage Capital Partners Gp, L.L.C. Prothena Corp Public LTD CO Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $4.21 Million - $7.33 Million	-100,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$48.2 - $78.89 $4.82 Million - $7.89 Million	-100,000 Reduced 50.0%	100,000 $7.12 Million
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $4.33 Million - $11.5 Million	200,000 New	200,000 $10.3 Million
Q1 2021 May 17, 2021	SELL	$11.0 - $28.24 $1.38 Million - $3.53 Million	-125,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $758,999 - $1.05 Million	-75,000 Reduced 37.5%	125,000 $1.5 Million
Q3 2020 Nov 16, 2020	BUY	$9.93 - $13.47 $1.74 Million - $2.36 Million	175,000 Added 700.0%	200,000 $2 Million
Q2 2020 Aug 14, 2020	BUY	$9.56 - $12.51 $239,000 - $312,750	25,000 New	25,000 $262,000

186

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $726M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.